← Leaderboards
Davendra Sohal
University Of Cincinnati
$1,764,005
Attributed
$1,764,005
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $492.2K · FY2020–24$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
Funding mix
By agency
FDA$1,764,005 · 1
By mechanism
R01$1,764,005 · 1
Top collaborators
No co-investigators on record.
Grant awards (4)
Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action inpancreatic cancer (Protocol sent on 20th June 2019 as an amendment of the IND 137394)$321,772
R01 · FY2024 · FD · contact PI
Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action inpancreatic cancer (Protocol sent on 20th June 2019 as an amendment of the IND 137394)$492,233
R01 · FY2023 · FD · contact PI
Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action inpancreatic cancer (Protocol sent on 20th June 2019 as an amendment of the IND 137394)$480,000
R01 · FY2022 · FD · contact PI
Phase I/II clinical evaluation of ABTL0812, a novel PI3K/Akt/mTOR inhibitor, with a unique mechanism of action inpancreatic cancer (Protocol sent on 20th June 2019 as an amendment of the IND 137394)$470,000
R01 · FY2020 · FD · contact PI